We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-1.01%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.36B
AUM Growth
-$447M
Cap. Flow
-$196M
Cap. Flow %
-4.5%
Top 10 Hldgs %
45.02%
Holding
102
New
10
Increased
31
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$183M
2
ARGX icon
argenx
ARGX
+$128M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$108M
4
JNJ icon
Johnson & Johnson
JNJ
+$97.3M
5
HUM icon
Humana
HUM
+$95M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$194M
2
BAX icon
Baxter International
BAX
+$149M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$146M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$115M
5
ABBV icon
AbbVie
ABBV
+$109M

Sector Composition

Rank Sector Weight
1 Healthcare 95.35%
2 Financials 0.54%
3 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
51
Jazz Pharmaceuticals
JAZZ
$15.4B
$9.67M 0.22%
+62,000
New +$9.54M
ALPN
52
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.5M 0.2%
998,565
-208,435
-17% -$1.8M
EPIX
53
DELISTED
ESSA Pharma
EPIX
$7.75M 0.18%
2,460,000
– –
IPSC icon
54
Century Therapeutics
IPSC
$402M
$7.27M 0.17%
865,000
– –
ERAS icon
55
Erasca
ERAS
$6.68B
$5.54M 0.13%
995,000
– –
CYT
56
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$5.53M 0.13%
1,850,000
– –
ANTX icon
57
AN2 Therapeutics
ANTX
$178M
$5.33M 0.12%
688,330
– –
CMPX icon
58
Compass Therapeutics
CMPX
$367M
$5.3M 0.12%
2,000,000
– –
MSAC
59
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$5.09M 0.12%
520,000
– –
BLSA
60
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.95M 0.11%
500,000
– –
ARYD
61
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$4.91M 0.11%
500,000
– –
PANA
62
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.88M 0.11%
500,000
– –
S icon
63
SentinelOne
S
$6.81B
$4.77M 0.11%
204,500
– –
ISEE
64
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.14M 0.1%
430,117
-6,045,283
-93% -$75.9M
OBIO icon
65
Orchestra BioMed
OBIO
$222M
$3.98M 0.09%
400,000
– –
TNGX icon
66
Tango Therapeutics
TNGX
$4.56B
$3.69M 0.08%
813,640
+92,640
+13% +$561K
HYPR icon
67
Hyperfine
HYPR
$95.8M
$3.35M 0.08%
1,503,754
– –
CMAX
68
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$2.74M 0.06%
25,178
– –
PHAS
69
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.64M 0.06%
4,405,000
– –
REUN
70
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$2.5M 0.06%
595,200
– –
ONCS
71
DELISTED
OncoSec Medical Incorporated
ONCS
$2.19M 0.05%
133,864
– –
OTIC
72
DELISTED
Otonomy, Inc.
OTIC
$2.08M 0.05%
1,000,000
-349,905
-26% -$728K
PROK icon
73
ProKidney
PROK
$326M
$1.99M 0.05%
200,000
– –
AKLI
74
DELISTED
Akili Inc
AKLI
$1.98M 0.05%
200,000
– –
LENZ
75
LENZ Therapeutics
LENZ
$159M
$1.95M 0.04%
101,429
– –
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
CM
Columbus Macro New Castle, Pennsylvania $936M AUM 12.9% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return

Avidity Partners Management's Q2 2022 Portfolio in Review

As of Q2 2022, Avidity Partners Management held 102 positions worth $4.36B, down 9.3% from $4.8B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Avidity Partners Management withdrew a net $196M in Q2 2022, closing 20 positions and reducing 13 holdings. Its most notable exit was Merck, an estimated $194M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Financials and Technology.

Against the trend, Avidity Partners Management opened a new position in Eli Lilly worth $198M.

  • Avidity Partners Management's largest Q2 2022 buy was Eli Lilly: 610,000 shares worth $198M.
  • Avidity Partners Management added most to argenx in Q2 2022, an estimated $128M increase.
  • Avidity Partners Management's biggest Q2 2022 reduction was AbbVie, cutting an estimated $109M.
  • Avidity Partners Management fully exited Merck in Q2 2022, selling an estimated $194M.
  • Avidity Partners Management's ten largest holdings make up 45% of its $4.36B portfolio in Q2 2022.
  • Avidity Partners Management opened 10 new positions and closed 20 in Q2 2022.
  • Avidity Partners Management's portfolio value fell 9.3% quarter-over-quarter to $4.36B.

Based on Avidity Partners Management's 13F filing for Q2 2022, filed 15 Aug 2022.